
European Commission Fines Teva €462.6 Million for Misusing Divisional patents and Disparaging Generic Competitors in the ...
On October 31, 2024, the European Commission (the Commission) delivered its long-awaited decision in the Teva Copaxone case (which was published on April 8, 2025). Teva, a global pharmaceutical company, was fined EUR 462.6 million for abusing its dominant …